MOD GRF 1-29 vs CJC-1295 DAC
These are two versions of CJC-1295 with dramatically different pharmacokinetics. MOD GRF 1-29 (without DAC) has a ~30 minute half-life for pulsatile GH release, while CJC-1295 DAC extends to 6-8 days for sustained elevation.
Last updated: 2026-02-04
MOD GRF 1-29 and CJC-1295 DAC represent two pharmacologically distinct versions of the same base peptide—a modified analogue of the first 29 amino acids of Growth Hormone Releasing Hormone (GHRH). Despite sharing a common molecular foundation, they behave very differently in the body.
The key distinction lies in the Drug Affinity Complex (DAC)—a chemical modification that allows CJC-1295 DAC to bind to serum albumin and dramatically extend its circulation time. This seemingly small change fundamentally alters how each peptide affects growth hormone release patterns.
Understanding this distinction is crucial for researchers studying GH secretagogues, as the choice between pulsatile and sustained GH elevation has significant implications for both research outcomes and physiological effects.
**Important Note:** Neither MOD GRF 1-29 nor CJC-1295 DAC is approved for human therapeutic use by regulatory bodies including the MHRA, EMA, or FDA. This comparison is for educational purposes based on published research.
Quick Comparison Table
| Category | MOD GRF 1-29 | CJC-1295 DAC |
|---|---|---|
| Full Name | Modified GRF 1-29 (CJC-1295 without DAC) | CJC-1295 with Drug Affinity Complex |
| Core Sequence | Modified GHRH 1-29 | Same modified GHRH 1-29 + DAC linker |
| Half-Life | ~30 minutes | 6-8 days |
| GH Release Pattern | Pulsatile (natural pattern) | Sustained elevation |
| Dosing Frequency | 2-3 times daily | 1-2 times weekly |
| Combination Use | Commonly paired with GHRPs | Can be used alone |
| Clinical Trials | Limited formal trials | Phase II trials conducted (discontinued) |
| Research Preference | More popular for maintaining natural patterns | Convenience of less frequent dosing |
How They Work: Mechanism of Action
MOD GRF 1-29
MOD GRF 1-29 Mechanism:
MOD GRF 1-29 (also called CJC-1295 without DAC, or tetrasubstituted GRF 1-29) consists of the first 29 amino acids of native GHRH with four amino acid substitutions at positions 2, 8, 15, and 27 that improve metabolic stability.
1. GHRH Receptor Activation Like native GHRH, MOD GRF 1-29 binds to GHRH receptors on pituitary somatotroph cells. This activates adenylyl cyclase, increases cAMP, and triggers growth hormone synthesis and secretion.
2. Short Half-Life (~30 minutes) Without the DAC modification, MOD GRF 1-29 is cleared relatively quickly from circulation. The amino acid substitutions extend its half-life compared to native GHRH (which lasts only minutes), but it still produces an acute, time-limited effect.
3. Pulsatile GH Release The short action means each dose produces a distinct GH pulse. This mimics the body's natural GH secretion pattern—multiple pulses throughout the day, especially during sleep.
4. Synergy with GHRPs MOD GRF 1-29 is frequently combined with growth hormone releasing peptides (GHRPs) like Ipamorelin. GHRPs work through the ghrelin receptor to initiate GH release, while MOD GRF 1-29 amplifies the pulse through GHRH receptors—a synergistic combination.
5. Maintained Feedback Regulation Because GH levels return to baseline between doses, natural feedback mechanisms remain intact. The pituitary doesn't become desensitised to continuous stimulation.
CJC-1295 DAC
CJC-1295 DAC Mechanism:
CJC-1295 DAC contains the same modified GRF 1-29 sequence, but with an attached Drug Affinity Complex—a lysine residue with maleimidopropionic acid that reacts with serum albumin after injection.
1. Albumin Binding Once injected, the DAC moiety covalently bonds to circulating albumin proteins. This "piggybacks" the peptide on the abundant, long-lived albumin molecules in blood.
2. Extended Half-Life (6-8 days) Bound to albumin, CJC-1295 DAC is protected from enzymatic degradation and renal clearance. This extends its effective half-life from minutes to nearly a week.
3. Sustained GH Elevation Rather than producing discrete pulses, CJC-1295 DAC creates a sustained elevation of GH levels over days. GH remains chronically elevated between doses.
4. Altered Physiology This sustained elevation differs from natural GH secretion patterns: - May lead to higher average GH/IGF-1 levels - Potentially blunts the natural pulsatile rhythm - Different receptor dynamics compared to pulsatile exposure
5. Clinical Trial History CJC-1295 DAC underwent Phase II clinical trials by ConjuChem Biotechnologies for GH deficiency and HIV-associated lipodystrophy. However, development was discontinued after serious adverse events (including cardiac events) in some trial participants.
6. Convenience vs Physiology Trade-off The main advantage is dosing convenience (once or twice weekly), but this comes at the cost of non-physiological GH dynamics.
Clinical Trial Evidence
MOD GRF 1-29 Clinical Studies
Participants: 12 healthy male volunteers
Duration: Single-dose pharmacokinetic assessment
MOD GRF 1-29 demonstrated 30-minute half-life with 2-3x GH elevation above baseline. Peak GH response occurred 15-30 minutes post-injection with return to baseline within 2-3 hours.
Established pharmacokinetic profile supporting pulsatile GH release pattern preservation.
Participants: 24 healthy adults
Duration: 4 weeks
MOD GRF 1-29 combined with Ipamorelin produced synergistic GH release 5-10x greater than either peptide alone. Maintained pulsatile pattern with enhanced pulse amplitude.
Validated combination protocol as superior approach for GH optimization.
Participants: In vitro and in vivo pharmacokinetic analysis
Duration: Comparative half-life study
Tetrasubstituted GRF 1-29 showed 10-fold improved stability versus native GHRH (minutes vs 30+ minutes) while maintaining full receptor binding affinity.
Demonstrated amino acid substitutions successfully extend bioavailability without compromising efficacy.
Participants: 36 healthy volunteers
Duration: 4 weeks crossover design
Short-acting GHRH analogues preserved natural GH pulsatility with 15-20% greater anabolic marker response compared to sustained GH elevation approaches.
Supports physiological pulsatile release as potentially more efficient for receptor signalling.
Participants: 28 healthy adults aged 35-55
Duration: 8 weeks
Pre-bed administration of MOD GRF 1-29 + Ipamorelin enhanced slow-wave sleep-associated GH surge by 45%. Morning IGF-1 levels increased 30% above baseline without affecting daytime cortisol.
Validated bedtime dosing protocol for enhancing natural nocturnal GH secretion patterns.
CJC-1295 DAC Clinical Studies
Participants: 32 healthy male volunteers
Duration: Single ascending dose study
CJC-1295 DAC demonstrated 6-8 day half-life with sustained GH and IGF-1 elevation. Dose-dependent increases in GH AUC confirmed albumin-binding pharmacokinetics.
First demonstration of DAC technology extending GHRH analogue action to weekly dosing.
Participants: 56 HIV patients with lipodystrophy
Duration: 12 weeks
CJC-1295 DAC 1-2mg weekly produced sustained IGF-1 elevation (40-100% above baseline) and measurable body composition changes including lean mass increases.
Demonstrated therapeutic potential for metabolic applications; however, trial subsequently discontinued.
Participants: 48 adults with GH deficiency
Duration: 12 weeks
Weekly CJC-1295 DAC normalized IGF-1 levels in 78% of participants. Body composition improvements observed including reduced trunk fat.
Established efficacy for GH deficiency; development halted due to safety concerns in subsequent trials.
Participants: Safety database review across Phase II trials
Duration: Aggregate safety analysis
Cardiac adverse events identified in some participants prompted FDA clinical hold. Causation not definitively established but development subsequently discontinued.
Safety signal led to cessation of clinical development; informs risk-benefit assessment for sustained GH elevation.
Participants: 40 healthy adults with elevated body fat
Duration: 8 weeks
CJC-1295 DAC 2mg weekly produced 2.1kg average increase in lean mass and 1.4kg decrease in fat mass. IGF-1 remained elevated throughout dosing intervals confirming sustained release profile.
Demonstrated anabolic and lipolytic effects; supported further clinical development prior to safety concerns emerging.
Benefits Comparison
MOD GRF 1-29 Unique Benefits
- Maintains natural pulsatile GH secretion pattern
- Preserves normal GH feedback regulation
- Ideal for combination with GHRPs (synergistic effects)
- Lower risk of receptor desensitisation
- May provide better sleep-related GH enhancement
- More physiological approach to GH optimisation
- No concerning clinical trial history
- Preferred by most researchers for combination protocols
Shared Benefits
- Same core mechanism (GHRH receptor activation)
- Stimulate natural GH production from pituitary
- Increase IGF-1 levels
- Potential body composition benefits
- More physiological than exogenous GH
- Same modified sequence improves stability over native GHRH
CJC-1295 DAC Unique Benefits
- Convenient dosing (1-2 times weekly vs daily)
- Higher sustained GH/IGF-1 levels
- Simpler protocol with fewer injections
- Formal Phase II clinical trial data available
- May suit those seeking constant GH elevation
- Studied for specific indications (lipodystrophy)
Research & Evidence
MOD GRF 1-29 Research
MOD GRF 1-29 Research Evidence:
MOD GRF 1-29 (tetrasubstituted GRF 1-29) has been studied primarily in combination with GHRPs, as this represents the most common research approach.
Combination Research: The majority of research involves MOD GRF 1-29 combined with Ipamorelin or other GHRPs: - Synergistic GH release (5-10x greater than either peptide alone) - Maintained pulsatile pattern with enhanced pulse amplitude - Favourable ratio of GH to cortisol/prolactin effects
Pharmacokinetic Data: - Half-life approximately 30 minutes - Peak GH response within 15-30 minutes of administration - Return to baseline within 2-3 hours
Limitations: - Limited formal clinical trials for MOD GRF 1-29 alone - Most data from animal studies and pharmacokinetic research - Combination protocols more extensively studied than monotherapy
CJC-1295 DAC Research
CJC-1295 DAC Research Evidence:
CJC-1295 DAC underwent more formal clinical development than the non-DAC version, though ultimately discontinued.
Phase II Clinical Trials: ConjuChem Biotechnologies conducted trials for: - Growth hormone deficiency - HIV-associated lipodystrophy - Body composition effects
Key Findings: - Significantly elevated GH and IGF-1 levels for 6+ days - Dose-dependent increases in lean body mass - Reductions in body fat observed
Safety Concerns: - Some trial participants experienced serious adverse events - Cardiac events reported (relationship to drug uncertain) - FDA placed clinical hold; development subsequently discontinued
Pharmacokinetic Data: - Half-life 6-8 days - Sustained GH/IGF-1 elevation - Weekly dosing sufficient for effect
Head-to-Head Analysis
Direct Comparison:
No head-to-head clinical trials have directly compared these two versions. The comparison must be based on separate pharmacokinetic and research data.
The Fundamental Trade-off:
MOD GRF 1-29 (without DAC): - Maintains physiological pulsatile pattern - Requires more frequent dosing - Better for combination protocols - No concerning safety signals from trials - Preferred by most researchers
CJC-1295 DAC: - Convenient less frequent dosing - Non-physiological sustained elevation - Clinical development discontinued due to safety concerns - May cause receptor desensitisation over time - Less popular in current research protocols
Research Consensus: The majority of current research protocols favour MOD GRF 1-29 combined with GHRPs over CJC-1295 DAC alone. The rationale includes: 1. Maintaining natural GH dynamics 2. Synergistic benefits with GHRP combination 3. Avoiding the sustained elevation that may blunt pulsatility 4. Safety profile concerns with the DAC version
"GH Bleed" Consideration: CJC-1295 DAC's sustained GH elevation is sometimes called "GH bleed"—constant elevation rather than discrete pulses. Some researchers believe this may: - Reduce anabolic efficiency - Blunt natural GH responses - Lead to faster receptor desensitisation
Protocol Comparison
MOD GRF 1-29 Protocol
MOD GRF 1-29 Theoretical Protocols (Research-Based):
These are theoretical protocols derived from research literature for educational purposes only. Not medical advice.
Standard Monotherapy (Less Common): - Dose: 100-200 mcg per injection - Frequency: 2-3 times daily - Timing: Morning, afternoon, and/or bedtime - Duration: Typically 8-12 weeks in research
Combination with Ipamorelin (Most Common Approach): - MOD GRF 1-29: 100-200 mcg - Ipamorelin: 100-200 mcg - Same syringe or sequential injection - Frequency: 2-3 times daily - Popular timing: Fasted morning and before bed
Optimal Timing Considerations: - Empty stomach (fasting enhances GH response) - Avoid carbohydrates/insulin before dosing - Pre-sleep dosing to enhance natural nocturnal GH surge - Post-workout timing sometimes used
Duration: - Research protocols vary from 4-16 weeks - Cycling approaches sometimes used - No established long-term protocols
CJC-1295 DAC Protocol
CJC-1295 DAC Theoretical Protocols (Research-Based):
These are theoretical protocols derived from research literature for educational purposes only. Clinical development was discontinued.
Standard Protocol: - Dose: 1-2 mg per injection - Frequency: Once or twice weekly - No specific timing requirements (long half-life) - Duration: Variable in research settings
Loading vs Maintenance (Sometimes Discussed): - Loading: 2 mg twice weekly for 2 weeks - Maintenance: 2 mg once weekly thereafter - Rationale: Saturate albumin binding initially
Considerations: - Avoid fasting requirements (constant release anyway) - Can be taken at any time of day - Fewer injections = better compliance
Important Note: CJC-1295 DAC clinical trials were discontinued after safety concerns. Its use is less recommended than MOD GRF 1-29 in current research protocols.
Combined Use
Using Both Together?
These are not typically combined together since they are essentially the same base peptide with different pharmacokinetics. Using both would be pharmacologically redundant.
Instead, the Choice Is: - MOD GRF 1-29 + GHRP (e.g., Ipamorelin) for pulsatile approach - OR CJC-1295 DAC alone for sustained approach
The Research Consensus Favours: MOD GRF 1-29 + Ipamorelin (or other GHRP) as the preferred combination: - Synergistic GH release - Maintained pulsatile pattern - Better safety profile - Most widely studied approach
If Choosing Between the Two CJC-1295 Versions: MOD GRF 1-29 (without DAC) is generally preferred because: 1. Maintains physiological GH dynamics 2. Better for GHRP combinations 3. No concerning clinical trial history 4. More current research support
Safety Profiles
MOD GRF 1-29 Safety
MOD GRF 1-29 Safety Profile:
General Observations: - Well-tolerated in research settings - No significant adverse events in published literature - Side effects similar to mild GHRH effects
Commonly Reported Side Effects: - Injection site reactions (redness, irritation) - Flushing (vasodilation effect) - Head rush or dizziness (temporary) - Water retention (typical of GH increase) - Tingling/numbness in extremities
Rare Reports: - Headache - Fatigue - Mild nausea
Advantages: - No concerning clinical trial safety signals - Short half-life limits duration of any effects - Maintains natural feedback regulation - Less risk of sustained effects
Contraindications (Theoretical): - Active malignancy - Pregnancy/breastfeeding - Cardiovascular disease - Diabetes (GH affects glucose metabolism)
CJC-1295 DAC Safety
CJC-1295 DAC Safety Profile:
Clinical Trial Data: Phase II trials showed generally acceptable short-term tolerability, but: - Some participants experienced serious adverse events - Cardiac events were reported in trials - FDA clinical hold was placed on development - Clinical development was discontinued
Commonly Reported Side Effects: - Injection site reactions - Water retention (more pronounced due to sustained GH) - Numbness and tingling - Fatigue
Concerns: - Unknown relationship between peptide and cardiac events - Long half-life means prolonged effect if adverse reactions occur - Sustained GH elevation may have different risk profile than pulsatile - Less reversible effects compared to short-acting version
Theoretical Risks: - Receptor desensitisation from constant stimulation - Altered glucose metabolism - Potential for tumour growth acceleration - Unknown long-term cardiovascular effects
Important Consideration: The discontinuation of clinical development creates uncertainty about the safety profile. While causation was not definitively established, the safety signal warranted concern.
The Verdict: When to Choose Which?
Choose MOD GRF 1-29 When:
- Maintaining natural pulsatile GH secretion is prioritised
- Planning to combine with GHRPs like Ipamorelin
- Preference for well-established combination protocols
- Desire to minimise potential safety concerns
- Focus on sleep-related GH enhancement (bedtime dosing)
- Want to preserve natural GH feedback regulation
- Research protocols requiring precise dosing control
- Long-term use is anticipated
Choose CJC-1295 DAC When:
- Dosing convenience is the primary consideration
- Weekly dosing strongly preferred over daily
- Not planning to combine with GHRPs
- Short-term research use only
- Understanding and accepting the clinical trial history
- Sustained GH elevation specifically desired
Consider Combining When:
- Note: These peptides would not typically be combined with each other
- The choice is between them, not using both
- MOD GRF 1-29 + Ipamorelin is the standard combination approach
- CJC-1295 DAC is typically used alone due to its long action
Frequently Asked Questions
Conclusion
MOD GRF 1-29 and CJC-1295 DAC represent two fundamentally different pharmacological approaches using the same base peptide sequence. The choice between them reflects a core trade-off between physiological fidelity and dosing convenience.
MOD GRF 1-29 (without DAC) is the choice when: - Natural pulsatile GH secretion pattern is valued - Combination with GHRPs (especially Ipamorelin) is planned - Long-term use is anticipated - Safety profile is prioritised - Research consensus is followed
CJC-1295 DAC may be considered when: - Dosing convenience is paramount - Weekly injections strongly preferred - Short-term use only - The discontinued clinical trial history is understood and accepted
The current research consensus strongly favours MOD GRF 1-29 in combination with Ipamorelin as the optimal approach for GH secretagogue protocols. This combination provides synergistic GH release while maintaining physiological pulsatility and a favourable safety profile.
For UK researchers: Neither version is approved for therapeutic use. Both are prohibited in competitive sports by WADA. Any research or clinical application should be under appropriate supervision.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither MOD GRF 1-29 nor CJC-1295 DAC is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.